ABOUT NovaUCDNovaUCD is responsible for the commercialisation of intellectual property (IP) arising from UCD research and for the development of partnerships with industry and business. NovaUCD's support for innovation and knowledge transfer is built around 4 key areas:
Promoting a culture of innovation and entrepreneurship
An ethos of innovation, knowledge transfer and commercialisation is embedded within UCD's research community through a series of dedicated training courses and related events.
Managing technology transfer
NovaUCD identifies, captures and commercialises the IP arising from UCD research programmes, whenever possible, for the benefit of enterprise development in Ireland. This includes licensing to commercial partners and creating spin-out companies.
Supporting and incubating new ventures
NovaUCD supports entrepreneurs and start-up companies from the early feasibility stage through to business development, growthand investment by providing support services, programmes and incubation facilities. Examples ofestablished UCD spin-out companies include:
Building partnerships
Bridging the gap between academic research and industry, and building relationships with industry is a key element of NovaUCD's commercialisation strategy.
In the past eight years, over 60 high-tech and knowledge intensive companies have occupied incubation space at NovaUCD and availed of NovaUCD's innovation services. Since 1996, 187 new ventures have completed NovaUCD's Campus Company Development Programme.
The total investment and realisation in UCD spin-out companies over the past decade is now in excess of €175M. In December 2008 ChangingWorlds was acquired for €47M by Amdocs, the US-quoted technology company and in July 2011 BiancaMed was acquired by ResMed.Another notable technology transfer success is the development and licensing of a BSE test, which to date has generated over €2M in royalty income for UCD.
